1. National Institutes of Health State of the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. Sleep 2005;28:1049–1057.
2. Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative–hypnotic, with the GABAA receptor;Sullivan;J Pharmacol Exp Ther,2004
3. In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative–hypnotic;Foster;J Pharmacol Exp Ther,2004
4. Jochelson P, Chen TK, Farber R, Campbell B. Lack of pharmacological and pharmacokinetic tolerance following repeat dosing of indiplon (NBI-34060). Poster presentation at the 17th annual meeting of the Associated Professional Sleep Societies, June 3–8, 2003, Chicago, IL.
5. Bozigian H. Chen, TK, Gately N, Boyd M. Indiplon dose-proportional pharmacokinetics. Poster presentation at the annual meeting of the American College of Clinical Pharmacy, October 23–26, 2005, San Francisco, CA.